XTX Topco Ltd Acquires Shares of 14,189 LivaNova PLC (NASDAQ:LIVN)

XTX Topco Ltd purchased a new position in LivaNova PLC (NASDAQ:LIVN - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 14,189 shares of the company's stock, valued at approximately $557,000.

Several other large investors also recently bought and sold shares of LIVN. UMB Bank n.a. lifted its stake in LivaNova by 340.5% in the first quarter. UMB Bank n.a. now owns 837 shares of the company's stock worth $33,000 after acquiring an additional 647 shares during the period. CWM LLC increased its holdings in shares of LivaNova by 52.3% during the first quarter. CWM LLC now owns 871 shares of the company's stock valued at $34,000 after acquiring an additional 299 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after buying an additional 219 shares in the last quarter. Sterling Capital Management LLC lifted its position in shares of LivaNova by 800.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock valued at $75,000 after buying an additional 1,441 shares in the last quarter. Finally, Central Pacific Bank Trust Division lifted its position in shares of LivaNova by 7.0% during the 1st quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock valued at $173,000 after buying an additional 290 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

LivaNova Stock Up 0.7%

LIVN traded up $0.32 on Friday, reaching $48.84. The company's stock had a trading volume of 823,704 shares, compared to its average volume of 766,631. The stock has a 50 day moving average of $44.94 and a two-hundred day moving average of $42.78. The company has a quick ratio of 1.37, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $2.67 billion, a price-to-earnings ratio of -12.56 and a beta of 0.92. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $57.35.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.84 by $0.21. The firm had revenue of $352.50 million during the quarter, compared to the consensus estimate of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%. The firm's quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.93 earnings per share. As a group, analysts forecast that LivaNova PLC will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LIVN has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $64.00 target price on shares of LivaNova in a research report on Tuesday, May 13th. Robert W. Baird increased their target price on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Barclays decreased their target price on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 8th. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a research note on Tuesday, May 20th. Finally, Wall Street Zen raised LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $59.29.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.